SOX2 and primary cutaneous T-cell non-Hodgkin lymphoma: A collection of 96 agents were tested and 20 histone deacetylases could decrease the SOX2 level (figure 3A, online supplemental figure 3A), of which SAHA was chosen for the following experiments since SAHA has been approved for the treatment of cutaneous T-cell lymphoma.26 We confirmed that SAHA decreased SOX2 protein levels but not mRNA levels (figure 3B, online supplemental figure 3B).